1. Home
  2. AVDL vs SIBN Comparison

AVDL vs SIBN Comparison

Compare AVDL & SIBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVDL
  • SIBN
  • Stock Information
  • Founded
  • AVDL 2015
  • SIBN 2008
  • Country
  • AVDL Ireland
  • SIBN United States
  • Employees
  • AVDL N/A
  • SIBN N/A
  • Industry
  • AVDL Biotechnology: Pharmaceutical Preparations
  • SIBN Medical/Dental Instruments
  • Sector
  • AVDL Health Care
  • SIBN Health Care
  • Exchange
  • AVDL Nasdaq
  • SIBN Nasdaq
  • Market Cap
  • AVDL 784.6M
  • SIBN 805.4M
  • IPO Year
  • AVDL 1996
  • SIBN 2018
  • Fundamental
  • Price
  • AVDL $9.18
  • SIBN $16.39
  • Analyst Decision
  • AVDL Strong Buy
  • SIBN Strong Buy
  • Analyst Count
  • AVDL 6
  • SIBN 5
  • Target Price
  • AVDL $18.17
  • SIBN $24.40
  • AVG Volume (30 Days)
  • AVDL 1.3M
  • SIBN 451.8K
  • Earning Date
  • AVDL 08-07-2025
  • SIBN 08-04-2025
  • Dividend Yield
  • AVDL N/A
  • SIBN N/A
  • EPS Growth
  • AVDL N/A
  • SIBN N/A
  • EPS
  • AVDL N/A
  • SIBN N/A
  • Revenue
  • AVDL $194,450,000.00
  • SIBN $176,601,000.00
  • Revenue This Year
  • AVDL $56.88
  • SIBN $19.48
  • Revenue Next Year
  • AVDL $29.81
  • SIBN $16.86
  • P/E Ratio
  • AVDL N/A
  • SIBN N/A
  • Revenue Growth
  • AVDL 252.64
  • SIBN 22.60
  • 52 Week Low
  • AVDL $6.38
  • SIBN $11.70
  • 52 Week High
  • AVDL $17.30
  • SIBN $20.05
  • Technical
  • Relative Strength Index (RSI)
  • AVDL 47.63
  • SIBN 36.27
  • Support Level
  • AVDL $9.10
  • SIBN $17.35
  • Resistance Level
  • AVDL $9.76
  • SIBN $19.24
  • Average True Range (ATR)
  • AVDL 0.47
  • SIBN 0.61
  • MACD
  • AVDL -0.08
  • SIBN -0.40
  • Stochastic Oscillator
  • AVDL 14.29
  • SIBN 2.00

About AVDL Avadel Pharmaceuticals plc

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.

About SIBN SI-BONE Inc.

SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.

Share on Social Networks: